T
Ting Zhang
Researcher at Beijing University of Chemical Technology
Publications - 120
Citations - 696
Ting Zhang is an academic researcher from Beijing University of Chemical Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 114 publications receiving 126 citations.
Papers
More filters
Journal ArticleDOI
Photo-curing 3D printing technique and its challenges
TL;DR: Five industrial photocuring 3D printing technologies are introduced, which are SLA, DLP, LCD, CLIP and MJP, and the characters of the materials and the progress of the application of the technique in the biomedical field is overviewed.
Journal ArticleDOI
Industrial Silicon Molybdenum Mosi2 Heater Element for Electric Oven, 1800 Degree C U Shape Mosi2 Heater Molybdenum Disilicide Heating Element
Journal ArticleDOI
Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study
Ting Zhang,Lei Wu,Xiaolong Xu,Yadong Yuan,Rongmeng Jiang,Xi-xin Yan,Xin Zhang,Yong Gao,Huanxia Shang,Bo Lian,Jing Hu,Jian-Qiang Mei,Shucai Wu,Jingquan Liu +13 more
TL;DR: Preliminary findings indicate LH tablets may be effective in symptomatic COVID-19, especially in relieving coughing, as well as in chest computed tomography signs.
Journal ArticleDOI
Effectiveness of Lianhua Qingwen Capsule in Treatment of Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial.
Ting Zhang,Lei Wu,Xiaolong Xu,Yadong Yuan,Rongmeng Jiang,Xi-xin Yan,Xin Zhang,Yong Gao,Huanxia Shang,Jing Hu,Xuerui Wang,Jian-Qiang Mei,Shucai Wu,Jingquan Liu +13 more
TL;DR: Wang et al. as mentioned in this paper investigated the effectiveness of Lianhua Qingwen (LH) capsule on asymptomatic coronavirus disease 2019 (COVID-19) patients.
Journal ArticleDOI
Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.
Shun Lu,Yiping Zhang,Guojun Zhang,Jianying Zhou,Shundong Cang,Ying Chen,Gang Wu,Peiguo Cao,Dongqing Lv,Hong Jian,Chengshui Chen,Xiangming Jin,Panwen Tian,Kai Wang,Guanming Jiang,Gongyan Chen,Qun Chen,Hui Zhao,Cuimin Ding,Renhua Guo,Guoping Sun,Liyan Jiang,Zhe Liu,Jian Fang,Junquan Yang,Wu Zhuang,Yunpeng Liu,Jing Zhang,Yueyin Pan,Jun Chen,Qitao Yu,Min Zhao,Jiuwei Cui,Dian-fa Li,Tienan Yi,Zhuang Yu,Yan Yang,Yan Zhang,Xiuyi Zhi,Yunchao Huang,Rong Wu,Ling Chen,Aimin Zang,Lejie Cao,Qingsheng Li,Xiaoying Li,Yong Song,Donglin Wang,Shucai Zhang,Lieming Ding,Ting Zhang,Xiaobin Yuan,Lin Yao,Zhi-Qiang Shen +53 more
TL;DR: In this article , the authors evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR tyrosine kinase inhibitor (TKI) therapy.